Technical Analysis for ALXO - ALX Oncology Holdings Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.21 | -1.63% | -0.02 |
ALXO closed down 1.63 percent on Wednesday, November 20, 2024, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -1.63% | |
| New 52 Week Low | Weakness | -1.63% | |
| Lower Bollinger Band Touch | Weakness | -1.63% | |
| Oversold Stochastic | Weakness | -1.63% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| Up 1% | about 22 hours ago |
| 2x Volume Pace | 2 days ago |
| 1.5x Volume Pace | 2 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.825 |
| 52 Week Low | 1.19 |
| Average Volume | 683,038 |
| 200-Day Moving Average | 7.85 |
| 50-Day Moving Average | 1.63 |
| 20-Day Moving Average | 1.40 |
| 10-Day Moving Average | 1.34 |
| Average True Range | 0.11 |
| RSI (14) | 28.57 |
| ADX | 20.28 |
| +DI | 13.43 |
| -DI | 23.30 |
| Chandelier Exit (Long, 3 ATRs) | 1.43 |
| Chandelier Exit (Short, 3 ATRs) | 1.53 |
| Upper Bollinger Bands | 1.60 |
| Lower Bollinger Band | 1.20 |
| Percent B (%b) | 0.02 |
| BandWidth | 28.40 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.11 |
| MACD Histogram | -0.0054 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.27 | ||||
| Resistance 3 (R3) | 1.28 | 1.26 | 1.26 | ||
| Resistance 2 (R2) | 1.26 | 1.25 | 1.26 | 1.26 | |
| Resistance 1 (R1) | 1.24 | 1.24 | 1.23 | 1.23 | 1.25 |
| Pivot Point | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 |
| Support 1 (S1) | 1.20 | 1.21 | 1.19 | 1.19 | 1.17 |
| Support 2 (S2) | 1.18 | 1.20 | 1.18 | 1.16 | |
| Support 3 (S3) | 1.16 | 1.18 | 1.16 | ||
| Support 4 (S4) | 1.15 |
